Navigation Links
AvidBiotics Announces Research Collaboration with Full Spectrum Genetics

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2013 /PRNewswire/ -- AvidBiotics today announced a research collaboration with Full Spectrum Genetics for the purpose of optimizing multiple therapeutic protein candidates from AvidBiotics' Micacide™ protein immuno-oncology and antiviral platform.  AvidBiotics also announced that Bob DuBridge, Ph.D., Chief Executive Officer of Full Spectrum Genetics, has joined the AvidBiotics Scientific Advisory Board.


"Micacide™ proteins represent a new class of molecules that harness the innate cellular immune response to efficiently detect and destroy cancerous or virus-infected cells," said James L. Knighton, AvidBiotics' President. "Full Spectrum Genetics' MapEng™ technology enables the rapid, simultaneous screening of many protein variants, allowing us to quickly identify those molecules with the best binding properties for further development as potential therapeutics."

Under the terms of the agreement, Full Spectrum Genetics will be responsible for generating and analyzing a multitude of variants of up to five specified AvidBiotics' protein molecules using its MapEng™ platform. AvidBiotics will receive worldwide rights to develop and commercialize product candidates arising from the collaboration. Full Spectrum Genetics will receive an upfront payment and is eligible for additional milestones and royalties on successfully commercialized molecules. Additional terms of the agreement were not disclosed.

"Traditional methods to understand protein-ligand interactions that affect disease outcomes often yield incomplete information despite the considerable time and expense involved," said Dr. DuBridge. "Our MapEng™ platform is designed to generate these insights significantly faster, less expensively and in more detail than other technologies, thus enabling the engineering of optimized proteins for further development by AvidBiotics."

Bob DuBridge Biography

Bob DuBridge, Ph.D. is the CEO of Full Spectrum Genetics, a company that he founded in 2010. Prior to that, he was employed at PDL BioPharma, Inc. from 2003 to 2010, ultimately serving as Head of New Technologies, and before that at Eos Biotechnology from 1999, which was acquired by PDL in 2003. Dr. DuBridge has also held senior scientific and management positions at such biotechnology firms as Lynx Therapeutics, Cell Genesys, Inc. and Genentech, Inc. He received his Ph.D. in genetics from Stanford University.

About Full Spectrum Genetics

Founded in 2010, Full Spectrum Genetics, Inc. is a privately-held protein engineering platform and product company.  The Company's MapEng™ platform enables ultra-high throughput quantification of the effect on binding of every possible single amino acid substitution within a protein binding site.  The MapEng™ platform provides a comprehensive analysis of protein structure-function relationships, with multiple applications for generating better biotherapeutics and diagnostics.  Full Spectrum Genetics' activities cover the spectrum from antibody discovery to generating proteins with improved properties including modulation of binding affinity to one or more targets, de-immunization, humanization, half-life extension and increased stability.  For more information on Full Spectrum Genetics and its MapEng™ platform, visit

About AvidBiotics

AvidBiotics is a developer of novel, non-antibody proteins targeting bacteria, virus infected cells and cancers. AvidBiotics has two proprietary product platforms. The first is a new class of tailorable, targeted bactericidal agents for use in the treatment or prevention of specific bacterial infections or contaminations. AvidBiotics' second technology platform specifically flags virus-infected or cancerous cells for enhanced destruction by the Natural Killer and T-cells of the potent innate immunity system. AvidBiotics focuses on human therapeutic applications of its technologies, both on its own and in partnership with governmental agencies and research institutions, while taking advantage of further near-term collaborative opportunities offered by specific applications of its products and technology platforms in areas such as food safety, biodefense and animal husbandry. The company has a partnership with DuPont Nutrition & Health aimed at commercializing its antibacterial protein technology in the field of food safety. For more information on AvidBiotics, please visit the company's web site at

SOURCE AvidBiotics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neurotrope, Inc., Announces New Trading Symbol
2. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
3. Invibio Biomaterial Solutions Announces Global Launch of “PEEK-OPTIMA HA Enhanced Polymer”
4. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
5. Clinverse, Inc. Announces Strategic Partnership With OmniComm Systems, Inc.
6. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
7. JULABO USA Inc. Announces Update on Product Finder Tool
8. ATCC Announces Creation of Biomaterial Contributor Network
9. Suria Plastic Surgery Announces an Open House at Their Plantation, Florida Office
10. SCD-iBIO Announces Second International Forum on Commercializing Global Green
11. Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO
Post Your Comments:
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... Francisco, CA (PRWEB) , ... November 25, 2015 ... ... microbial genomics company uBiome, were featured on AngelList early in their initial angel ... launching an AngelList syndicate for individuals looking to make early stage investments in ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
Breaking Biology Technology:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Capacitive Fingerprint Sensors - Technology and Patent Infringement Risk ... --> --> Fingerprint sensors using ... smartphones. The fingerprint sensor vendor Idex forecasts an increase ... in mobile devices and of the fingerprint sensor market ...
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
Breaking Biology News(10 mins):